Vector Develops Three More COVID-19 Vaccines Apart From EpiVacCorona

Russia’s research center Vector is developing three coronavirus vaccines apart from the one that has been already registered, they are in different phases of trials, the country’s consumer rights watchdog Rospotrebnadzor said, as reported by Sputnik.

“Taking into consideration the results obtained through experiments, we have chosen four vaccines for COVID-19 prevention that we see as promising ones. They are currently in different stages of trials. There is a peptide vaccine, a recombinant vaccine based on the vesicular stomatitis virus, a recombinant vaccine based on the influenza A virus and a recombinant vaccine based on the measles virus,” the watchdog said in a statement.

On October 13, the peptide vaccine EpiVacCorona, developed by Vector, became Russia’s second registered vaccine against COVID-19.

On 11 August, the country registered the world’s first COVID-19 vaccine, Sputnik V, which was developed by the Gamaleya Research Institute with support from the Russian Direct Investment Fund (RDIF).